Literature DB >> 27122574

Comparison of Antibody-Dependent Cell-Mediated Cytotoxicity and Virus Neutralization by HIV-1 Env-Specific Monoclonal Antibodies.

Benjamin von Bredow1, Juan F Arias1, Lisa N Heyer2, Brian Moldt3, Khoa Le3, James E Robinson4, Susan Zolla-Pazner5, Dennis R Burton3,6,7, David T Evans8,9.   

Abstract

UNLABELLED: Although antibodies to the human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein have been studied extensively for their ability to block viral infectivity, little data are currently available on nonneutralizing functions of these antibodies, such as their ability to eliminate virus-infected cells by antibody-dependent cell-mediated cytotoxicity (ADCC). HIV-1 Env-specific antibodies of diverse specificities, including potent broadly neutralizing and nonneutralizing antibodies, were therefore tested for ADCC against cells infected with a lab-adapted HIV-1 isolate (HIV-1NL4-3), a primary HIV-1 isolate (HIV-1JR-FL), and a simian-human immunodeficiency virus (SHIV) adapted for pathogenic infection of rhesus macaques (SHIVAD8-EO). In accordance with the sensitivity of these viruses to neutralization, HIV-1NL4-3-infected cells were considerably more sensitive to ADCC, both in terms of the number of antibodies and magnitude of responses, than cells infected with HIV-1JR-FL or SHIVAD8-EO ADCC activity generally correlated with antibody binding to Env on the surfaces of virus-infected cells and with viral neutralization; however, neutralization was not always predictive of ADCC, as instances of ADCC in the absence of detectable neutralization, and vice versa, were observed. These results reveal incomplete overlap in the specificities of antibodies that mediate these antiviral activities and provide insights into the relationship between ADCC and neutralization important for the development of antibody-based vaccines and therapies for combating HIV-1 infection. IMPORTANCE: This study provides fundamental insights into the relationship between antibody-dependent cell-mediated cytotoxicity (ADCC) and virus neutralization that may help to guide the development of antibody-based vaccines and immunotherapies for the prevention and treatment of HIV-1 infection.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27122574      PMCID: PMC4907221          DOI: 10.1128/JVI.00347-16

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  106 in total

1.  Two immunodominant domains of gp41 bind antibodies which enhance human immunodeficiency virus type 1 infection in vitro.

Authors:  W E Robinson; M K Gorny; J Y Xu; W M Mitchell; S Zolla-Pazner
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

2.  Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family.

Authors:  Mattia Bonsignori; Justin Pollara; M Anthony Moody; Michael D Alpert; Xi Chen; Kwan-Ki Hwang; Peter B Gilbert; Ying Huang; Thaddeus C Gurley; Daniel M Kozink; Dawn J Marshall; John F Whitesides; Chun-Yen Tsao; Jaranit Kaewkungwal; Sorachai Nitayaphan; Punnee Pitisuttithum; Supachai Rerks-Ngarm; Jerome H Kim; Nelson L Michael; Georgia D Tomaras; David C Montefiori; George K Lewis; Anthony DeVico; David T Evans; Guido Ferrari; Hua-Xin Liao; Barton F Haynes
Journal:  J Virol       Date:  2012-08-15       Impact factor: 5.103

3.  Sustained antibody-dependent cell-mediated cytotoxicity (ADCC) in SIV-infected macaques correlates with delayed progression to AIDS.

Authors:  Nia D Banks; Nicole Kinsey; Janice Clements; James E K Hildreth
Journal:  AIDS Res Hum Retroviruses       Date:  2002-11-01       Impact factor: 2.205

4.  Independent evolution of Fc- and Fab-mediated HIV-1-specific antiviral antibody activity following acute infection.

Authors:  Anne-Sophie Dugast; Leonidas Stamatatos; Andrew Tonelli; Todd J Suscovich; Anna F Licht; Iliyana Mikell; Margaret E Ackerman; Hendrik Streeck; P J Klasse; John P Moore; Galit Alter
Journal:  Eur J Immunol       Date:  2014-08-11       Impact factor: 5.532

5.  An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1 serum.

Authors:  Guido Ferrari; Justin Pollara; Daniel Kozink; Tiara Harms; Mark Drinker; Stephanie Freel; M Anthony Moody; S Munir Alam; Georgia D Tomaras; Christina Ochsenbauer; John C Kappes; George M Shaw; James A Hoxie; James E Robinson; Barton F Haynes
Journal:  J Virol       Date:  2011-05-04       Impact factor: 5.103

6.  Antibody-dependent cellular cytotoxicity against primary HIV-infected CD4+ T cells is directly associated with the magnitude of surface IgG binding.

Authors:  Adjoa Smalls-Mantey; Nicole Doria-Rose; Rachel Klein; Andy Patamawenu; Stephen A Migueles; Sung-Youl Ko; Claire W Hallahan; Hing Wong; Bai Liu; Lijing You; Johannes Scheid; John C Kappes; Christina Ochsenbauer; Gary J Nabel; John R Mascola; Mark Connors
Journal:  J Virol       Date:  2012-06-06       Impact factor: 5.103

7.  Antibody neutralization and escape by HIV-1.

Authors:  Xiping Wei; Julie M Decker; Shuyi Wang; Huxiong Hui; John C Kappes; Xiaoyun Wu; Jesus F Salazar-Gonzalez; Maria G Salazar; J Michael Kilby; Michael S Saag; Natalia L Komarova; Martin A Nowak; Beatrice H Hahn; Peter D Kwong; George M Shaw
Journal:  Nature       Date:  2003-03-20       Impact factor: 49.962

8.  Antibodies purified from sera of HIV-1-infected patients by affinity on the heptad repeat region 1/heptad repeat region 2 complex of gp41 neutralize HIV-1 primary isolates.

Authors:  Nadine Vincent; Amadou Kone; Blandine Chanut; Frédéric Lucht; Christian Genin; Etienne Malvoisin
Journal:  AIDS       Date:  2008-10-18       Impact factor: 4.177

9.  Protection against mucosal simian immunodeficiency virus SIV(mac251) challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting.

Authors:  L Jean Patterson; Nina Malkevitch; David Venzon; Joel Pinczewski; Victor Raúl Gómez-Román; Liqun Wang; V S Kalyanaraman; Phillip D Markham; Frank A Robey; Marjorie Robert-Guroff
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

10.  Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys.

Authors:  Dan H Barouch; James B Whitney; Brian Moldt; Florian Klein; Thiago Y Oliveira; Jinyan Liu; Kathryn E Stephenson; Hui-Wen Chang; Karthik Shekhar; Sanjana Gupta; Joseph P Nkolola; Michael S Seaman; Kaitlin M Smith; Erica N Borducchi; Crystal Cabral; Jeffrey Y Smith; Stephen Blackmore; Srisowmya Sanisetty; James R Perry; Matthew Beck; Mark G Lewis; William Rinaldi; Arup K Chakraborty; Pascal Poignard; Michel C Nussenzweig; Dennis R Burton
Journal:  Nature       Date:  2013-10-30       Impact factor: 49.962

View more
  71 in total

Review 1.  Beyond Viral Neutralization.

Authors:  George K Lewis; Marzena Pazgier; David T Evans; Guido Ferrari; Stylianos Bournazos; Matthew S Parsons; Nicole F Bernard; Andrés Finzi
Journal:  AIDS Res Hum Retroviruses       Date:  2017-02-16       Impact factor: 2.205

2.  Anti-HIV-1 ADCC Antibodies following Latency Reversal and Treatment Interruption.

Authors:  Wen Shi Lee; Anne B Kristensen; Thomas A Rasmussen; Martin Tolstrup; Lars Østergaard; Ole S Søgaard; Bruce D Wines; P Mark Hogarth; Arnold Reynaldi; Miles P Davenport; Sean Emery; Janaki Amin; David A Cooper; Virginia L Kan; Julie Fox; Henning Gruell; Matthew S Parsons; Stephen J Kent
Journal:  J Virol       Date:  2017-07-12       Impact factor: 5.103

Review 3.  Antibody-dependent cellular cytotoxicity in HIV infection.

Authors:  Donald N Forthal; Andrés Finzi
Journal:  AIDS       Date:  2018-11-13       Impact factor: 4.177

4.  Contribution of NK Cell Education to both Direct and Anti-HIV-1 Antibody-Dependent NK Cell Functions.

Authors:  Anne B Kristensen; Stephen J Kent; Matthew S Parsons
Journal:  J Virol       Date:  2018-05-14       Impact factor: 5.103

5.  CD4- and Time-Dependent Susceptibility of HIV-1-Infected Cells to Antibody-Dependent Cellular Cytotoxicity.

Authors:  Wen Shi Lee; Jérémie Prévost; Jonathan Richard; Reneé M van der Sluis; Sharon R Lewin; Marzena Pazgier; Andrés Finzi; Matthew S Parsons; Stephen J Kent
Journal:  J Virol       Date:  2019-05-01       Impact factor: 5.103

6.  Flow Cytometry Analysis of HIV-1 Env Conformations at the Surface of Infected Cells and Virions: Role of Nef, CD4, and SERINC5.

Authors:  Isabelle Staropoli; Jérémy Dufloo; Olivier Schwartz; Nicoletta Casartelli; Anaïs Ducher; Pierre-Henri Commere; Anna Sartori-Rupp; Sophie Novault; Timothée Bruel; Valérie Lorin; Hugo Mouquet
Journal:  J Virol       Date:  2020-02-28       Impact factor: 5.103

7.  Comprehensive Cross-Clade Characterization of Antibody-Mediated Recognition, Complement-Mediated Lysis, and Cell-Mediated Cytotoxicity of HIV-1 Envelope-Specific Antibodies toward Eradication of the HIV-1 Reservoir.

Authors:  Shariq Mujib; Jun Liu; A K M Nur-Ur Rahman; Jordan A Schwartz; Phil Bonner; Feng Yun Yue; Mario A Ostrowski
Journal:  J Virol       Date:  2017-07-27       Impact factor: 5.103

8.  Improved killing of HIV-infected cells using three neutralizing and non-neutralizing antibodies.

Authors:  Marina Tuyishime; Carolina Garrido; Shalini Jha; Matt Moeser; Dieter Mielke; Celia LaBranche; David Montefiori; Barton F Haynes; Sarah Joseph; David M Margolis; Guido Ferrari
Journal:  J Clin Invest       Date:  2020-10-01       Impact factor: 14.808

9.  Lack of ADCC Breadth of Human Nonneutralizing Anti-HIV-1 Antibodies.

Authors:  Timothée Bruel; Florence Guivel-Benhassine; Valérie Lorin; Hugues Lortat-Jacob; Françoise Baleux; Katia Bourdic; Nicolas Noël; Olivier Lambotte; Hugo Mouquet; Olivier Schwartz
Journal:  J Virol       Date:  2017-03-29       Impact factor: 5.103

10.  Envelope glycoproteins sampling states 2/3 are susceptible to ADCC by sera from HIV-1-infected individuals.

Authors:  Jérémie Prévost; Jonathan Richard; Shilei Ding; Beatriz Pacheco; Roxanne Charlebois; Beatrice H Hahn; Daniel E Kaufmann; Andrés Finzi
Journal:  Virology       Date:  2017-12-15       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.